CN116531469A - 一种用于宠物下泌尿综合症的治疗药物及其应用 - Google Patents
一种用于宠物下泌尿综合症的治疗药物及其应用 Download PDFInfo
- Publication number
- CN116531469A CN116531469A CN202310378951.1A CN202310378951A CN116531469A CN 116531469 A CN116531469 A CN 116531469A CN 202310378951 A CN202310378951 A CN 202310378951A CN 116531469 A CN116531469 A CN 116531469A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- treating
- syndrome
- rhizome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 63
- 230000002485 urinary effect Effects 0.000 title claims abstract description 62
- 229940126585 therapeutic drug Drugs 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 174
- 239000003814 drug Substances 0.000 claims abstract description 109
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 17
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims abstract description 17
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims abstract description 17
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims abstract description 17
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 17
- 229940046009 vitamin E Drugs 0.000 claims abstract description 17
- 239000011709 vitamin E Substances 0.000 claims abstract description 17
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 16
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 16
- 235000013717 Houttuynia Nutrition 0.000 claims abstract description 15
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 14
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 14
- 241000287828 Gallus gallus Species 0.000 claims abstract description 13
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 12
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 12
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 11
- 241000522190 Desmodium Species 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 3
- 235000004554 glutamine Nutrition 0.000 claims abstract description 3
- 229960002743 glutamine Drugs 0.000 claims abstract description 3
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 4
- 241000123069 Ocyurus chrysurus Species 0.000 claims abstract 4
- 235000015097 nutrients Nutrition 0.000 claims description 26
- 241000282326 Felis catus Species 0.000 claims description 23
- 241001598107 Imperata Species 0.000 claims description 18
- 241001106477 Paeoniaceae Species 0.000 claims description 13
- 235000019206 astragalus extract Nutrition 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 11
- 241000219061 Rheum Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 241001571764 Lysimachia christinae Species 0.000 claims description 5
- 240000004980 Rheum officinale Species 0.000 claims description 5
- 235000008081 Rheum officinale Nutrition 0.000 claims description 5
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 241000243684 Lumbricus Species 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 32
- 208000002193 Pain Diseases 0.000 abstract description 22
- 210000001635 urinary tract Anatomy 0.000 abstract description 19
- 239000003826 tablet Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 13
- 235000016709 nutrition Nutrition 0.000 abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000004087 circulation Effects 0.000 abstract description 7
- 239000002934 diuretic Substances 0.000 abstract description 7
- 230000001882 diuretic effect Effects 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000273 veterinary drug Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 34
- 230000027939 micturition Effects 0.000 description 24
- 239000013642 negative control Substances 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 210000003932 urinary bladder Anatomy 0.000 description 15
- 208000009911 Urinary Calculi Diseases 0.000 description 12
- 208000019206 urinary tract infection Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241001127637 Plantago Species 0.000 description 10
- 241001149655 Rubia tinctorum Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000012931 Urologic disease Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 208000014001 urinary system disease Diseases 0.000 description 8
- 239000004575 stone Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 241000112528 Ligusticum striatum Species 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 206010007027 Calculus urinary Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000008281 urolithiasis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 4
- 206010064921 Urinary tract inflammation Diseases 0.000 description 4
- 208000028938 Urination disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 230000036318 urination frequency Effects 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010061397 Urinary tract injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001614060 Amynthas aspergillus Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010006987 Calculus bladder Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000076686 Queensland pidgeon grass Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038381 Renal atrophy Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 240000009235 Rubia cordifolia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 235000003232 Setaria pumila ssp. pallide fusca Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 201000000210 bladder calculus Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于宠物下泌尿综合症的治疗药物及其应用,属于兽药领域,具体涉及一种地龙、鱼腥草、黄芪、白茅根、车前草、川芎、茜草、白芍、白术、金钱草、鸡内金和大黄12种天然药物的提取物与谷氨酰胺、L‑赖氨酸、维生素E、盐酸吡哆醇4种营养剂配制而成。该治疗药物为片剂、胶囊、颗粒剂或散剂任一种。本发明集抗炎、利尿、排石、止痛、修复于一体,具备清热抗炎、通淋排石,强化营养支持和平衡机体水液循环的功效,适用于宠物下泌尿道综合症的治疗,功效显著,安全性高,制备方法简单,操作方便,适合工业化生产。
Description
技术领域
本发明属于兽药技术领域,具体涉及一种用于宠物下泌尿综合症的治疗药物及其应用。
背景技术
近年来,宠物经济如火如荼的发展,宠物犬猫的饲养量逐年攀升,随之其健康问题亦逐渐显现,其中泌尿系统问题尤其下泌尿道疾病更为被关注。
宠物临床中,下泌尿道疾病较常见,疾病常见症状为尿频、尿痛、尿淋漓、排尿困难、血尿以及乱排尿、尿闭为主,常见疾病有下泌尿道感染、尿路结石、特发性膀胱炎等。典型症状为排尿障碍(排尿次数减少、尿淋漓、尿不尽、血尿、频繁排尿动物但排尿量较少、尿闭)、尿路结晶/结石(下泌尿道主要包括膀胱和输尿管,尿路中形成晶核,金属元素如钙、镁等形成不溶性盐等是结石形成的主要原因)、尿路炎症、腹部疼痛等给犬猫带来一系列的不适症状,严重的继发尿路感染及其他病理变化。
临床上有手术治疗宠物下泌尿道疾病,虽效果确切,复发几率小,但是仍然存在复发的风险,并且手术疗法对机体损伤较大,若动物机体状态良好,临床症状不严重,建议采取保守疗法进行治疗。
CN112715751A公开了一种犬猫用泌尿道保护饲料添加剂及其制备方法,该添加剂包括重量比例为10~40份的猫须草提取物、20~40份的车前子、5~10份的姜黄粉以及40~60份的分散剂,所述分散剂为麦麸。该添加剂在添加量为1%左右时,即可使犬猫的饮水量显著上升,增加排尿量和排尿次数,使血清中所积累的代谢终产物随之排出。
CN111214538A公开了一种防治犬猫下泌尿道疾病的组合物及其咀嚼片及制备方法,该咀嚼片按质量分数计,由以下组分组成:活性成分30-40%;粘合剂1.8-2.4%;保湿剂10-15%;乳化剂5-7%;风味剂8-10%;抗氧化剂3-4%;防腐剂0.5-1%;崩解剂5-7%;润滑剂0.1-1%;其余为填充剂,所述活性成分包括柳叶栎提取物、虾蟹壳提取物、蔓越莓提取物和金钱草提取物。
CN106819506A公开了一种防尿路结石的饲料添加剂,按重量百分含量计由下述组分组成:别嘌呤醇20~30%、乳酶生25~32%、柠檬酸镁23~34%、水杨酸钠0.2~4%、烟酰胺0.3~0.9%、中草药药汁4~9%。
上述专利申请均主要利用中草药为主要功能组分,辅以分散剂、风味剂等制成,从功能上主要是增加宠物饮水排尿、控制尿酸形成等。此外,目前临床治疗中以西药为主,不同药物主成分治疗功效单一,对症不全面。如N-乙酰葡萄糖胺仅修复膀胱壁黏膜、蔓越莓仅有抗炎功效、氯化铵仅具有酸化尿液功效等。但从目前临床病例来看,犬猫泌尿道结石及下泌尿道损伤并非单发,而多是渐进性复合发生。因此上述方案其并不能解决这一难题。
因此,急需开发一种集抗炎、利尿、排石、止痛、修复于一体,既清热抗炎、通淋排石,又强化营养支持,平衡机体水液循环,适用于宠物下泌尿道综合症治疗的新药。
发明内容
本发明的目的在于开发一款集抗炎、利尿、排石、止痛、修复于一体,既清热抗炎、通淋排石,又强化营养支持,平衡机体水液循环,用于宠物下泌尿道综合症治疗的新药。
本发明提供解决宠物临床针对下泌尿道疾病治疗药物功效单一,不全面的问题,特别是针对排尿障碍(排尿次数减少、尿淋漓、尿不尽、血尿、频繁排尿动物但排尿量较少、尿闭)、尿路结晶/结石(下泌尿道主要包括膀胱和输尿管)、尿路炎症或腹部疼痛等2种及以上宠物下泌尿道病症治疗问题的解决。
基于上述情况,本发明所要解决的第一个技术问题是提供一种用于宠物下泌尿综合症的治疗药物。
本发明所要解决的第二个技术问题是提供一种用于宠物下泌尿综合症治疗药物的给药剂型。
本发明所要解决的第三个技术问题是一种用于宠物下泌尿综合症的治疗药物在宠物下泌尿综合症治疗药物中的应用。
为解决上述第一个技术问题,本发明提供的技术方案是:
本发明提供一种用于宠物下泌尿综合症的治疗药物,由天然中药提取物和营养素配制而成,所述的天然中药提取物包括:地龙、鱼腥草、黄芪、白茅根、车前草、川芎、茜草、白芍、白术、金钱草、鸡内金、大黄的提取物。
所述的营养素包括:谷氨酰胺、L-赖氨酸、盐酸吡哆醇、维生素E。
具体地,组合物中的各味中药在方剂中所起作用为:
地龙为钜蚓科动物参环毛蚓Pheretima aspergillum(E.Perrier)的干燥体,习称“广地龙”。地龙提取物具备清热定惊,通络,平喘,利尿。用于高热神昏,惊痫抽搐,关节痹痛,肢体麻木,半身不遂,肺热喘咳,水肿尿少。
鱼腥草为三白草科植物蕺菜Houttuynia cordata Thunb.的新鲜全草或干燥地上部分。鱼腥草提取物具备清热解毒、利尿消肿等。现代药理实验表明,鱼腥草抗病毒、抗菌、免疫增强等作用明显,其提取物能使毛细血管扩张,增加血流量及尿液转化,从而具有利尿的作用。
黄芪为豆科植物膜荚黄芪Astragalus membranaceus(Fisch.)Bge.的干燥根黄芪补气升阳,补气,气推动水液循环,加速尿液排出,带出小结石;升阳,阳气充足,机体免疫力提高,减少肾炎的发生,预防水肿。
白茅根为禾本科植物白茅Imperata cylindrica Beauv.var.major(Nees)C.E.Hubb.的干燥根茎。白茅根提取物具备利尿、抗炎,对急性肾炎有较好效果,可以缩短病程。
车前草为车前科植物车前Plantago asiatica L.的干燥全草。车前草提取物具备清热、利水、通淋,邪热下达排出,排尿增多,增加尿量,冲洗出结晶;同时增加尿液中的尿素、尿酸、氯化钠的排出,减缓结石的形成。
川芎为伞形科植物川芎Ligusticum chuanxiong Hort.的干燥根茎。川芎提取物具备川芎疏通血脉,促进血液循环,止痛,利尿。现代药理证实,川芎内含川芎嗪、川芎酚,可有效防治肾病综合征,急、慢性肾衰竭,IgA肾病。
茜草为茜草科植物茜草Rubia cordifolia L.的干燥根和根茎。茜草提取物具备凉血,祛瘀,止血,通经。用于吐血,衄血,崩漏,外伤出血,瘀阻经闭,关节痹痛,跌扑肿痛。
白芍为毛茛科植物芍药Paeonia lactiflora Pall.的干燥根。白芍提取物具备缓急止痛,减缓疼痛症状,缓解疼痛导致的情绪问题。
白术为菊科植物白术Atractylodes macrocephala Koidz.的干燥根茎。白术提取物具备燥湿利水,健脾益气,止汗,安胎。用于脾虛食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。
金钱草为报春花科植物过路黄Lysimachia christinae Hance的干燥全草。金钱草提取物具备利湿退黄,利尿通淋,解毒消肿。用于尿涩作痛,黄疸尿赤、湿热黄疸,胆胀胁痛,石淋,热淋,小便涩痛,痈肿疔疮,蛇虫咬伤,肝胆结石,尿路结石。
鸡内金为雉科动物家鸡Callus gallus domesticus Brisson的干燥沙囊内壁。鸡内金提取物具备通淋化石,健胃消食,涩精止遗。用于食积不消,呕吐泻痢,小儿疳积,遗尿,遗精,石淋涩痛,胆胀胁痛。
大黄为药用大黄Rheum officinale Baill.的干燥根和根茎。大黄提取物具备利湿退黄,泻下攻积,清热泻火,凉血解毒,逐瘀通经。用于实热积滞便秘,血热吐衄,目赤咽肿,痈肿疔疮,肠痈腹痛,黄疸尿赤,淋证,水肿。
谷氨酰胺具备修复膀胱黏膜,保护膀胱内壁,避免下泌尿道综合症引起的水液代谢障碍;参与合成谷胱甘肽(一种重要的抗氧化剂),提高机体抗氧化能力,稳定细胞膜和蛋白质结构,维持肾脏、胰腺等重要器官的正常功能;同时又是营养增补剂,可增强免疫功能。
L-赖氨酸具备增进消化功能,促进产品有效成分的吸收;舒张血管,促进血液循环。
盐酸吡哆醇具备是天然的利尿剂,维持体内钠、钾平衡,调节体液;补充营养,保持身体处于健康状态。
天然维生素E是强抗氧化剂,对延缓肾脏病变、萎缩、衰竭、衰老、预防肾小管进一步硬化、斑痕化,减少肾脏出现斑痕非常的重要。
该用于宠物下泌尿综合症的治疗药物,所述的天然中药提取物按重量份计为:地龙1-5份、鱼腥草1-15份、黄芪2-20份、白茅根1-15份、车前草1-15份、川芎1-15份、茜草1-15份、白芍1-15份、白术1-15份、金钱草2-20份、鸡内金1-15份、大黄1-15份;
所述的营养素按重量份计为:谷氨酰胺1-6份、L-赖氨酸1-2份、盐酸吡哆醇1-3份、维生素E1-5份。
进一步的,该宠物下泌尿综合症的治疗药物所述的天然中药提取物按重量份计为:地龙提取物3-5份、鱼腥草提取物5-12份、黄芪提取物6-18份、白茅根提取物6-12份、车前草6-10份、川芎提取物3-9份、茜草提取物6-12份、白芍提取物6-12份、白术提取物6-12份、金钱草提取物6-18份、鸡内金提取物5-10份、大黄提取物3-9份;
所述的营养素按重量份计为:谷氨酰胺2-4份、L-赖氨酸1-2份、盐酸吡哆醇1-3份、维生素E2-4份。
进一步的,该宠物下泌尿综合症的治疗药物所述的天然中药提取物按重量份计为:地龙提取物5份、鱼腥草提取物9份、黄芪提取物12份、白茅根提取物9份、车前草提取物6份、川芎9份、茜草提取物9份、白芍提取物9份、白术提取物9份、金钱草提取物12份、鸡内金提取物6份、大黄提取物6份;
所述的营养素按重量份计为:谷氨酰胺3份、L-赖氨酸2份、盐酸吡哆醇1份、维生素E3份。
为解决上述第二个技术问题,本发明提供的技术方案是:
本发明提供一种宠物下泌尿综合症治疗药物发制剂,其给药剂型可以是固体制剂、半固体制剂或液体制剂。固体制剂优选为普通片、分散片、缓释片、胶囊、颗粒剂或者散剂,半固体制剂优选软膏剂、糊剂或者凝胶剂,液体制剂优选为糖浆剂或者口服溶液剂。
进一步,所述的一种宠物下泌尿综合症治疗药物的常用剂型,所述药物组合物的剂型为片剂、胶囊、颗粒剂或散剂任一种
一种宠物下泌尿综合症的治疗药物,主要应用对象为犬、猫、猪、兔、鼠等宠物。
进一步,本发明提供一种用于宠物下泌尿综合症治疗药物的丸剂制备方法,,所述制备方法包括,按组方量称取各中药提取物和营养素,混匀并过100目筛后,混合均匀得治疗药粉,加炼蜜制成小蜜丸,干燥,打光,装袋即得;每100g治疗药粉中,9.120-150g,制成小蜜丸,每丸含药量0.5g。
为解决上述第三个技术问题,本发明对所述的一种用于宠物下泌尿综合症治疗药物进行了宠物猫的下泌尿综合症治疗研究,详见具体实施方式下的实施例和临床典型案例。
本发明制备的宠物下泌尿综合症治疗药物及其制剂可有效预防及控制继发宠物泌尿道感染,缓解宠物因疼痛导致的情绪问题,减少酸性尿液对膀胱黏膜的损伤及刺激,是一款集抗炎、利尿、排石、止痛、修复于一体,既清热抗炎、通淋排石,又强化营养支持,平衡机体水液循环的用于宠物下泌尿道问题治疗的产品。给药形式多样,可满足宠物用药多种临床需求。病情案例、治疗效果参见具体实施方式的临床典型案例。
与现有技术相比,本发明具有如下的有益效果或优点。
1、本发明所述的宠物下泌尿综合症治疗药物由天然药材与营养素配制,具有利尿排石、粘膜修复、缓急止痛、清热抗炎的功效,同时解决宠物下泌尿道多种症状,对症较全面。
2、本发明所述的宠物下泌尿综合症治疗药物安全、无毒副反应、肝肾代谢负担小。
3、本发明所述的宠物下泌尿综合症治疗药物预防控制感染:对症治疗同时,预防及控制继发泌尿道感染。
4、本发明所述的宠物下泌尿综合症治疗药物可中药止痛舒郁:减缓疼痛症状,缓解疼痛导致的情绪问题。
5、本发明所述的宠物下泌尿综合症治疗药物可增强尿素、尿酸排泄:减少酸性尿液对膀胱黏膜的损伤及刺激。
5.本发明可制备为不同给药剂型,给药方式和给药剂量灵活多变,易于调整、方便操作。
6、本发明所述的宠物下泌尿综合症治疗药物为首款集抗炎、利尿、排石、止痛、修复于一体,既清热抗炎、通淋排石,又强化营养支持,平衡机体水液循环的用于宠物下泌尿道问题治疗的产品。给药形式多样,可满足宠物用药多种临床需求
7、本发明中述及的制剂的生产工艺简便,生产流程易于自动化,适合工业化生产。
具体实施方式
以下结合具体实施例,对本发明的具体实施方案做详细的阐述。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围,本发明的保护范围以权利要求为准,包括在此基础上所作出的显而易见的变化或变动等。
下述各实施例中所述实验方法和检测方法,如无特殊说明,均为常规方法;所述中药提取物、营养素、试剂和材料,如无特殊说明,均可在市场上购买得到。
实施例1
一种宠物下泌尿综合症的治疗药物,其中天然中药提取物按重量份计为:地龙提取物5份、鱼腥草提取物9份、黄芪提取物12份、白茅根提取物9份、车前草提取物6份、川芎提取物9份、茜草提取物9份、白芍提取物9份、白术提取物9份、金钱草提取物12份、鸡内金提取物6份、大黄提取物6份;
所述的营养素按重量份计为:谷氨酰胺3份、L-赖氨酸2份、盐酸吡哆醇1份、维生素E3份。
制备方法1,按上述组方量称取各中药提取物和营养素,加入辅料,混合均匀,制粒,压片,即可。每片含药量0.5g。
实施例2
一种宠物下泌尿综合症的治疗药物,其中天然中药提取物按重量份计为:地龙提取物5份、鱼腥草提取物9份、黄芪提取物12份、白茅根提取物9份、车前草提取物6份、川芎提取物9份、茜草提取物9份、白芍提取物9份、白术提取物9份、金钱草提取物12份、鸡内金提取物6份、大黄提取物6份;
所述的营养素按重量份计为:谷氨酰胺3份、L-赖氨酸2份、盐酸吡哆醇1份、维生素E3份。
制备方法2,按上述组方量称取各中药提取物和营养素,混匀并过100目筛后,混合均匀得治疗药粉,加炼蜜制成小蜜丸,干燥,打光,装袋即得;每100g治疗药粉中,加炼蜜125g,制成小蜜丸,每丸含药量0.5g。
实施例3
一种宠物下泌尿综合症的治疗药物,其中天然中药提取物按重量份计为:地龙提取物2份、鱼腥草提取物1份、黄芪提取物2份、白茅根提取物1份、车前草提取物1份、川芎提取物1份、茜草提取物1份、白芍提取物1份、白术提取物1份、金钱草提取物2份、鸡内金提取物1份、大黄提取物1份;
所述的营养素按重量份计为:谷氨酰胺1份、L-赖氨酸1份、盐酸吡哆醇1份、维生素E1份。
制备方法同实施例1,此处不在赘述。
实施例4
一种宠物下泌尿综合症的治疗药物,其中天然中药提取物按重量份计为:地龙提取物10份、鱼腥草提取物15份、黄芪提取物20份、白茅根提取物15份、车前草提取物15份、川芎提取物15份、茜草提取物15份、白芍提取物15份、白术提取物15份、金钱草提取物20份、鸡内金提取物15份、大黄提取物15份;
所述的营养素按重量份计为:谷氨酰胺6份、L-赖氨酸2份、盐酸吡哆醇3份、维生素E 5份。
制备方法同实施例1,此处不在赘述。
对比例1
一种宠物下泌尿综合症的治疗药物,只含有本申请的天然中药提取物。
按重量份计为:地龙提取物10份、鱼腥草提取物15份、黄芪提取物20份、白茅根提取物15份、车前草提取物15份、川芎提取物15份、茜草提取物15份、白芍提取物15份、白术提取物15份、金钱草提取物20份、鸡内金提取物15份、大黄提取物15份;
按上述组方量称取各中药提取物,按实施例1的制备方法,加入相同辅料,混合均匀,制粒,压片,即可。每片含药量0.5g。
对比例2
一种宠物下泌尿综合症的治疗药物,只含有本申请的营养素。
按重量份计为:谷氨酰胺6份、L-赖氨酸2份、盐酸吡哆醇3份、维生素E5份。
按上述组方量称取各营养素,按实施例1的制备方法,加入相同辅料,混合均匀,制粒,压片,即可。每片含药量0.5g。
对比例3
一种宠物下泌尿综合症的治疗药物,不含本申请鱼腥草提取物和白茅根提取物成分,考察两者对抗炎方面的影响。
天然中药提取物按重量份计为:地龙提取物10份、黄芪提取物20份、车前草提取物15份、川芎提取物15份、茜草提取物15份、白芍提取物15份、白术提取物15份、金钱草提取物20份、鸡内金提取物15份、大黄提取物15份;
所述的营养素按重量份计为:谷氨酰胺6份、L-赖氨酸2份、盐酸吡哆醇3份、维生素E 5份。
制备方法同实施例1,此处不在赘述。
对比例4
一种宠物下泌尿综合症的治疗药物,不含本申请车前草提取物、金钱草提取物和鸡内金提取物,考察这三种提取物在排石方面对本申请的影响。
天然中药提取物按重量份计为:地龙提取物10份、鱼腥草提取物15份、黄芪提取物20份、白茅根提取物15份、川芎提取物15份、茜草提取物15份、白芍提取物15份、白术提取物15份、大黄提取物15份;
所述的营养素按重量份计为:谷氨酰胺6份、L-赖氨酸2份、盐酸吡哆醇3份、维生素E 5份。
制备方法同实施例1,此处不在赘述。
实验例1
关于本申请宠物下泌尿综合症治疗药物的药效试验
在陕西省西安市多家宠物医院,进行为期2年的药效试验。
病例纳入标准:临床症状表现为排尿障碍(排尿次数减少、尿淋漓、尿不尽、血尿、频繁排尿动物但排尿量较少、尿闭)、尿路结晶/结石(下泌尿道主要包括膀胱和输尿管)、尿路炎症或腹部疼痛的2种及以上病症。
病证确认和治疗效果检测方法:
临床基础检查涵盖问诊、触诊、尿道探诊,确认初步临床症状和病史;
尿液检查为尿液常规检测可辅助疾病的诊断;
B型超声检查:可显示检查部位的切面图像,能直观的显示被扫查脏器的大小、形态和内部结构,协助推断病情;
X-ray检查:通过肾脏、膀胱和尿道的影像,可以快速准确的诊断出尿路损伤、结石、肿瘤、畸形等疾病;
血液学检查涵盖血常规检查、血清生化检查、血液气体分析、血液离子检查,考虑到动物性别、年龄等情况,通过综合分析,对具体疾病做出诊断。
在此期间,符合上述症状患有下泌尿综合症的自然发病宠物猫为验证对象,且宠物猫的品种、体重、病情严重程度、症状表现一致,经宠物主人同意,共有224只宠物猫参与研究,详见诊断病症统计结果表1。
将每次同时患病的宠物猫平均分为3组,每组喂养方法一致,每组用药之后的药效具有可比性。
表1诊断病症统计结果表
7个实验组分别为:
阳性药物组:选用实施例1制备的宠物下泌尿综合症治疗药物的药片,每片含药量0.5g。每日服用3次,服用量为1g/kg体重,将药片混合在食物中直接饲喂,按照宠物食物量与药量比5:1;
阴性对照1组:选用对比例1制备的宠物下泌尿综合症治疗药物的药片,与阳性药物组同时间饲喂,饲喂方法一致;
阴性对照2组:选用对比例2制备的宠物下泌尿综合症治疗药物的药片,与阳性药物组同时间饲喂,饲喂方法一致;
阴性对照3组:选用对比例3制备的宠物下泌尿综合症治疗药物的药片,与阳性药物组同时间饲喂,饲喂方法一致;
阴性对照4组:选用对比例4制备的宠物下泌尿综合症治疗药物的药片,与阳性药物组同时间饲喂,饲喂方法一致;
中药对照组:选用知母黄柏散,治疗膀胱及尿道结石,与阳性药物组同时间饲喂,饲喂方法一致,用量按照临床指导用量;
西药对照组:选用尿痛舒,治疗下尿路感染,与阳性药物组同时间饲喂,饲喂方法一致,用量按照临床指导用量。
治疗疗效:
治愈:治疗效果临床检查判定为正常;
复发:症状完全消失后,1月内出现部分或全部病症。
以2个月(每月按30天计)为一个疗程;过程符合治愈判定标准,计为治愈病例数;后1月内再次临床诊断为复发,计为复发病例数,治疗效果如表2所示:
表2治疗周期内药物效果表
治疗药物组别/(32例) | 治愈/例 | 复发/例 |
阳性药物组 | 30 | 2 |
阴性对照1组 | 22 | 6 |
阴性对照2组 | 1 | 0 |
阴性对照3组 | 7 | 1 |
阴性对照4组 | 16 | 5 |
中药对照组 | 9 | 3 |
西药对照组 | 18 | 8 |
各药物组治疗周期内各药物疗效表3所示:
表3各药物组治疗周期内各药物疗效表
治疗药物组别/(32例) | 治愈/例 | 治愈率 | 复发率 |
阳性药物组 | A:8;B:12;C:5;D:4;E:1; | 93.75% | 6.67% |
阴性对照1组 | A:6;B:10;C:4;D:2;E:0; | 68.75% | 27.27% |
阴性对照2组 | A:0;B:1;C:0;D:0;E:0; | 3.13% | 0 |
阴性对照3组 | A:1;B:1;C:3;D:2;E:0; | 21.88% | 14.29% |
阴性对照4组 | A:5;B:9;C:4;D:1;E:0; | 50.00% | 31.25% |
中药对照组 | A:2;B:1;C:3;D:2;E:1; | 28.13% | 33.33% |
西药对照组 | A:6;B:9;C:2;D:1;E:0; | 56.25% | 44.44% |
注:A指自发性下尿路感染膀胱结石;B:指下尿路感染;C:尿道结石;D:膀胱结石;E:膀胱及尿道结石
治愈率=痊愈的总数量/每个实验组病例总量(32例)*100%
复发率=复发总数量/痊愈总数量*100%
实用结果及分析:
(1)阳性药物组治愈患下泌尿综合症的自然发病宠物猫治愈率高达93.75%,复发率仅为6.67%;临床常用中药对照组的知母黄柏散治愈患下泌尿综合症的自然发病宠物猫治愈率为28.13%,但复发率高达33.33%;临场常用西药对照组的尿痛舒治愈患下泌尿综合症的自然发病宠物猫治愈率为56.25%,但复发率也高达44.44%。
(2)从治疗自发性膀胱炎和下尿路感染的相关病例对比可知,在治愈宠物猫下泌尿感染,即抗炎方面可知,治愈病例数阳性药物组>西药对照组(主治下尿路感染)>阴性对照1组(本申请中药提取物组成部分)>阴性对照4组(本申请缺排石类组分)>中药对照组(主治治疗膀胱及尿道结石)>阴性对照3组(本申请缺抗炎类组分)>阴性对照2组(本申请营养素类组分)
(3)从治疗膀胱结石、尿道结石、膀胱及尿道结石的相关病例对比可知,在治愈宠物猫下泌尿结石类疾病,治愈病例数阳性药物组>阴性对照1组(本申请中药提取物组成部分)≥中药对照组(主治治疗膀胱及尿道结石)>阴性对照3组(本申请缺抗炎类组分)>西药对照组(主治下尿路感染)>阴性对照4组(本申请缺排石类组分)>阴性对照2组(本申请营养素类组分)
(4)从治愈后复发率可知,西药对照组(主治下尿路感染)治愈复发率最高,中药对照组次之,本申请阳性药物组药物组最低,
综合上述实验结果和本申请个药物组分功效,可知宠物下泌尿综合症治疗药物具备抗炎、利尿、排石、止痛和修复于一体,清热抗炎、通淋排石。同时解决宠物临床针对下泌尿道疾病治疗药物中药或西药功效单一,不全面的问题,特别是针对排尿障碍(排尿次数减少、尿淋漓、尿不尽、血尿、频繁排尿动物但排尿量较少、尿闭)、尿路结晶/结石(下泌尿道主要包括膀胱和输尿管)、尿路炎症或腹部疼痛等2种及以上宠物下泌尿道病症的治疗。同时,本申请的宠物下泌尿综合症治疗药物治愈率高、复发率低,具有显著的治疗效果,可广泛用于临床治疗宠物下泌尿综合症。
临床典型案例
病例一:银渐层(猫),4岁,雄,4.2kg,该病例最初表现排尿困难,尿频,膀胱部位临床敏感(触诊宠物表现为挣扎)。B超显示膀胱体积异常增大,尿液中有大量絮状物,尿检多项指标异常。
治疗:放置尿管,口服本申请实施例1制备的宠物下泌尿综合症治疗药片/每日两次,第一天导出的尿液中镜检可见大量红细胞,用药第2天尿量明显增多,猫咪腹部敏感度降低(触诊宠物表现为不安、回视),用药四天后尿液中红细胞和结晶明显减少。
病例二:英国短毛猫,2岁,雄,6kg,该病例临床表现为尿闭,影像学检查膀胱底部有大量游离高密度物质,最终诊断为下泌尿道阻塞。X-ray检查影像学提示为尿道结石,尿检多项指标异常。
治疗:镇静后导尿,口服本申请实施例3制备的宠物下泌尿综合症治疗药片/每日两次。第一天导出的尿液中可见大量白色半透明细小结晶,镜检可见尿液中存在大量血红蛋白!用药5天后尿液颜色基本恢复正常。
病例三:英国短毛猫,3岁,雄,4kg,近两天发现猫频繁蹲猫砂盆,尿量少,地板有淡粉色液体。X-ray检查影像学提示为膀胱结石,尿检多项指标异常。
治疗:口服本申请实施例4制备的宠物下泌尿综合症治疗药片,每日2次,一个月后复查x光片提示结石已消失,尿液量达到正常同体重猫每日平均尿液量、尿色恢复正常、尿检合格。
综上,本发明的宠物下泌尿综合症的治疗药物集抗炎、利尿、排石、止痛、修复于一体,具有清热抗炎、通淋排石,强化营养支持和平衡机体水液循环的功效。适用于宠物下泌尿道综合症的治疗。该宠物下泌尿综合症的治疗药物治疗效果佳,复发率低,可作为治疗宠物下泌尿综合症的首选临床用药。
本发明的上述实施例仅是为了较为清楚地说明本发明而作的举例,并非是对本发明实施方式的限定。对于相关领域的技术人员来说,在上述说明和举例的基础上还可以做出其他各种形式的调整和变动。本说明书无法对所有的实施方式予以穷举。凡是属于本发明的技术方案所引伸出的显而易见的调整和变动仍处于本发明的保护范围之列。
Claims (10)
1.一种用于宠物下泌尿综合症的治疗药物,由天然中药提取物和营养素配制而成,其特征在于,所述的天然中药提取物包括:地龙、鱼腥草、黄芪、白茅根、车前草、川芎、茜草、白芍、白术、金钱草、鸡内金、大黄的提取物。
2.根据权利要求1所述的治疗药物,其特征在于,所述的营养素包括:谷氨酰胺、L-赖氨酸、盐酸吡哆醇、维生素E。
3.根据权利要求1所述的治疗药物,其特征在于,所述的天然中药提取物对按重量份计为:地龙提取物1-5份、鱼腥草提取物1-15份、黄芪提取物2-20份、白茅根提取物1-15份、车前草提取物1-15份、川芎提取物1-15份、茜草提取物1-15份、白芍提取物1-15份、白术提取物1-15份、金钱草提取物2-20份、鸡内金提取物1-15份、大黄提取物1-15份;
所述的营养素按重量份计为:谷氨酰胺1-6份、L-赖氨酸1-2份、盐酸吡哆醇1-3份、维生素E1-5份。
4.根据权利要求1所述的治疗药物,其特征在于,所述的天然中药提取物按重量份计为:地龙提取物3-5份、鱼腥草提取物5-12份、黄芪提取物6-18份、白茅根提取物6-12份、车前草提取物6-10份、川芎提取物3-9份、茜草提取物6-12份、白芍提取物6-12份、白术提取物6-12份、金钱草提取物6-18份、鸡内金提取物5-10份、大黄提取物3-9份;
所述的营养素按重量份计为:谷氨酰胺2-4份、L-赖氨酸1-2份、盐酸吡哆醇1-3份、维生素E 2-4份。
5.根据权利要求1所述的治疗药物,其特征在,所述的天然中药提取物按重量份计为:地龙提取物5份、鱼腥草提取物9份、黄芪提取物12份、白茅根提取物9份、车前草提取物6份、川芎提取物9份、茜草提取物9份、白芍提取物9份、白术提取物9份、金钱草提取物12份、鸡内金提取物6份、大黄提取物6份;
所述的营养素按重量份计为:谷氨酰胺3份、L-赖氨酸2份、盐酸吡哆醇1份、维生素E 3份。
6.根据权利要求1-5任一项所述的一种宠物下泌尿综合症的治疗药物,其特征在于,所述药物组合物的剂型为片剂、胶囊、颗粒剂或散剂任一种。
7.根据权利要求1-5所述的一种宠物下泌尿综合症的治疗药物,其特征在于,所述药物组合物的应用对象为犬、猫、猪、兔或鼠任一种。
8.一种如权利要求1-5所述用于宠物下泌尿综合症治疗药物的制备方法,其特征在于,所述用于宠物下泌尿综合症治疗药物的剂型为丸剂,所述制备方法包括,按组方量称取各中药提取物和营养素,混匀并过100目筛后,混合均匀得治疗药粉,加炼蜜制成小蜜丸,干燥,打光,装袋即得。
9.根据权利要求8所述的制备方法,其特征在于,每100g治疗药粉中,加炼蜜120-150g,制成小蜜丸,每丸含药量0.5g。
10.权利要求1-5任一项所述的治疗药物在制备治疗宠物下泌尿综合症的兽药中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310378951.1A CN116531469A (zh) | 2023-04-11 | 2023-04-11 | 一种用于宠物下泌尿综合症的治疗药物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310378951.1A CN116531469A (zh) | 2023-04-11 | 2023-04-11 | 一种用于宠物下泌尿综合症的治疗药物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116531469A true CN116531469A (zh) | 2023-08-04 |
Family
ID=87453242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310378951.1A Pending CN116531469A (zh) | 2023-04-11 | 2023-04-11 | 一种用于宠物下泌尿综合症的治疗药物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116531469A (zh) |
-
2023
- 2023-04-11 CN CN202310378951.1A patent/CN116531469A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101049415A (zh) | 一种治疗妇科炎症的中药组合物 | |
CN103830577B (zh) | 一种治疗肝胆结石和肾结石的药物组合物及其用途 | |
WO2012031525A1 (zh) | 一种促情助孕的中药组合物 | |
CN104800773B (zh) | 一种用于防治新产奶牛子宫疾病的中药组合物及其制备方法 | |
CN1559470A (zh) | 一种牲畜用中成药 | |
CN106668185A (zh) | 预防和治疗牛羊尿结石症的药物组合物 | |
CN113491743B (zh) | 一种防治禽痛风疾病的药物组合物及其制备方法与应用 | |
CN105012673A (zh) | 一种防治家畜霉菌毒素中毒的中药及其制备方法 | |
CN116531469A (zh) | 一种用于宠物下泌尿综合症的治疗药物及其应用 | |
CN104043042A (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN104825753B (zh) | 一种通过母猪服药防治新生仔猪腹泻的中药组合物 | |
CN104548016A (zh) | 一种中药组合物在制备治疗高尿酸血症药物中的用途 | |
CN103585583B (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN110755489A (zh) | 一种治疗痛风的中药及其制备方法 | |
CN102008647B (zh) | 一种治疗淋巴管平滑肌瘤的中药及其制备方法 | |
CN105434915A (zh) | 一种用于治疗犬猫泌尿道结石的药物组合物及其制备方法 | |
CN110960610A (zh) | 一种防治奶牛气虚型胎衣不下的中药组合物及其制备方法 | |
CN104147268B (zh) | 一种治疗肝胆结石的中药组合物及其制剂 | |
CN117281868B (zh) | 一种防治母猪繁殖障碍的中兽药组合物及其制备方法和用途 | |
CN115804815B (zh) | 一种防治妊娠母猪便秘的中药组合物及其制备方法 | |
CN102935129B (zh) | 用于清消痤疮的药物组合物及其制备方法 | |
CN108686003B (zh) | 一种治疗肾功能不全和不明原因蛋白尿的中药组合物及其制剂和应用 | |
CN100509003C (zh) | 一种治疗牛皮癣的药物 | |
CN104352629B (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN104027683A (zh) | 一种治疗猪膀胱炎的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231003 Address after: Room 435, Chuangye Building, No. 16 Shennong Road, Yangling Demonstration Zone, Xianyang City, Shaanxi Province, 712000 Applicant after: Shaanxi Zhuozhen Small Animal Health Industry R&D Center Co.,Ltd. Address before: No. 1, 2nd Floor, Unit 2, Building 10, No. 198 Xifeng Road, Chang'an District, Xi'an City, Shaanxi Province, 710100 Applicant before: Shaanxi Yingnuojia Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right |